GlassScriptPhysician profile
Kevin M Gooch
NPI 1164415576
$2,962.13
in general payments reported to CMS, 2019-2025
34 companies · $1,254 in 2025
The $1,254 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.90 · 2021: $166 · 2022: $293 · 2023: $446 · 2024: $787 · 2025: $1,254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,467 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,466.91 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $609.80 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $350.75 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $315.52 | 2021-2025 | |
| Pfizer INC. | $176.29 | 2021-2025 | |
| Lilly USA, LLC | $150.46 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Lundbeck LLC | $137.05 | 2024-2025 | Vyepti, Rexulti |
| Abbott Laboratories | $130.01 | 2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $126.20 | 2023-2025 | Farxiga, Airsupra, Fasenra |
| Amgen INC. | $109.00 | 2022-2025 | Repatha, Otezla, Krystexxa |
| Axsome Therapeutics, INC. | $78.47 | 2024-2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.36 | 2022-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $67.15 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $65.41 | 2023-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $60.23 | 2022-2023 | Eliquis |
| Esperion Therapeutics, INC. | $55.59 | 2024-2025 | Nexletol |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $51.81 | 2024-2025 | Gemtesa |
| Medtronic, INC. | $50.58 | 2022-2025 | Inceptiv, Minimed 780g |
| Xeris Pharmaceuticals, INC. | $43.05 | 2025 | Gvoke Hypopen |
| Vanda Pharmaceuticals INC. | $39.85 | 2024 | Fanapt |
| Astellas Pharma US INC | $34.09 | 2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.21 | 2023 | Xifaxan, Trulance |
| Tonix Medicines, INC. | $20.11 | 2025 | Tonmya |
| Viatris Specialty LLC | $18.80 | 2025 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $18.66 | 2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.22 | 2024 | Caplyta |
| Evoke Pharma, INC. | $17.49 | 2022 | |
| Teleflex LLC | $17.41 | 2024 | Urolift |
| Aimmune Therapeutics, INC. | $16.57 | 2024 | |
| Dexcom, INC. | $15.94 | 2024 | Dexcom G6 Transmitter |
| Allergan, INC. | $15.90 | 2020 | |
| Exact Sciences Corporation | $15.84 | 2023 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $15.57 | 2023 | Yupelri |
| Boston Scientific Corporation | $14.40 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Gooch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.